Market Research Report
Multaq (Atrial Fibrillation) - Analysis and Forecasts to 2022
|Published by||GlobalData||Product code||244305|
|Published||Content info||37 Pages
|Multaq (Atrial Fibrillation) - Analysis and Forecasts to 2022|
|Published: May 31, 2012||Content info: 37 Pages||
This publication has been discontinued on February 2, 2017.
GlobalData's pharmaceuticals report, "Multaq (Atrial Fibrillation) - Analysis and Forecasts to 2022" provides Multaq global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2009-2022). The report also includes information on Atrial Fibrillation market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Multaq, dronedarone, class III antiarrhythmic, paroxysmal atrial fibrillation, persistent atrial fibrillation, cardiovascular hospitalizations